New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - carvedilol 6.25mg - film coated tablet - 6.25 mg - active: carvedilol 6.25mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 400 magnesium stearate polysorbate 80 povidone purified water   sucrose titanium dioxide - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤ 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: pregnancy category c. studies performed in pregnant rats and rabbits given carvedilol revealed increased post-implantation loss in rats at doses of 300 mg/kg/day [50 times the maximum recommended human dose (mrhd) as mg/m2 ] and in rabbits at doses of 75 mg/kg/day (25 times the mrhd as mg/m2 ). in the rats, there was also a decrease in fetal body weight at the maternally toxic dose of 300 mg/kg/day (50 ti

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets, usp are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets, usp are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol tablets are contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol tablets. - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy.

United States - English - NLM (National Library of Medicine)

direct rx - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 25 mg - 1.2 left ventricular dysfunction following myocardial infarction carvedilol tablet is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies ( 14.2)]. 1.3 hypertension carvedilol tablet is indicated for the management of essential hypertension [see clinical studies ( 14.3, 14.4)]. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions ( 7.2)]. carvedilol tablet is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol tablet. - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - carvedilol 12.5mg;   - film coated tablet - 12.5 mg - active: carvedilol 12.5mg   excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-22-18096 povidone - hypertension dp-carvedilol is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (eg calcium channel blockers, diuretics).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - carvedilol 25mg;   - film coated tablet - 25 mg - active: carvedilol 25mg   excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-22-18096 povidone - hypertension dp-carvedilol is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (eg calcium channel blockers, diuretics).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - carvedilol 6.25mg;   - film coated tablet - 6.25 mg - active: carvedilol 6.25mg   excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-22-18096 povidone - hypertension dp-carvedilol is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (eg calcium channel blockers, diuretics).

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 400; crospovidone; povidone; lactose monohydrate; magnesium stearate; titanium dioxide; colloidal anhydrous silica; polysorbate 80; sucrose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - carvedilol - oral tablet - 3.125mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - carvedilol - oral tablet - 3.125mg